Breast Cancer

Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 252,710 American women will be diagnosed with breast cancer and 40,610 will die from the disease in 2017. For the majority (62%) of women with breast cancer, the disease is confined to the breast, and the 5-year survival approaches 100%. However, for women with metastatic disease, the likelihood of survival at 5 years drops to 27%.
Breast cancer affects more women than any other type of cancer, and represents 15% of all new cancer cases in the United States. A total of 252,710 new breast cancer cases were estimated to be diagnosed in 2017, and more than 40,600 deaths. The prognosis worsens for patients with locally advanced breast cancer and even more so for those with metastatic disease.
This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer.

For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase inhibitor in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results presented at the 2017 ESMO Congress.

Treatment with a regimen of pembrolizumab plus trastuzumab in patients with trastuzumab-resistant advanced HER2-positive breast cancer was well-tolerated and had clinical benefit in those whose tumors were positive for a biomarker for pembrolizumab.
Patients aged 40 years with breast cancer who underwent axillary lymph node dissection were more likely to experience arm swelling and decreased range of arm motion than patients who received less invasive sentinel lymph node biopsies.
According to the results of 2 recent analyses, dose-dense or dose-intense chemotherapy reduces the risk for breast cancer recurrence and improves survival compared with standard chemotherapy regimens.
In patients with HR-positive breast cancer, a positive circulating tumor cells assay result was associated with nearly a 20-fold increased risk for recurrence of disease.
Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who are treated with a CDK4/6 inhibitor may derive benefits similar to those seen in their younger counterparts.
At 10-year follow-up, investigators observed similar outcomes with exemestane alone and sequential tamoxifen/exemestane in the phase 3 TEAM trial of postmenopausal women with hormone receptor (HR)-positive early breast cancer.
Page 1 of 17
Results 1 - 10 of 170